bleak

SCOTTY T relies on money from his mum to stay afloat – as his lawyer calls the new dad’s bank balance “bleak”.

The finances of former Geordie Shore star – real name Scott Timlin – were laid bare as he appeared at Southwark Crown Court yesterday alongside Towie star Yazmin Oukhellou and Love Island star Jamie Clayton.

They all pleaded guilty to communicating an invitation or inducement to engage in investment opportunities.

The court heard Timlin has 2.7m followers on Instagram but he relies on nightclub appearances and his income from OnlyFans to make £34,000 a year.

Laura Miller, representing Timlin, said: ‘His post was scripted and he said what he was told to say. He accepts he was reckless.

“Mr Timlin is not a man of extensive means. He earns money via an agent but also does receive other money for example an OnlyFans.

CELEB SCAM

Towie & Love Island stars admit plugging dodgy investments in ‘finfluencer’ plot

SCOTTY’S HELL

‘I was out 7 days a week doing drugs’, says Scotty T as he opens up on arrest

“For the last 12 months his yearly income was around £34,000.

“As often said there is the Instagram world and the reality. Mr Timlin’s bank statements make it very clear the lifestyle he lives in the public eye is not the lifestyle he actually does lead.”

She said he relies on extra money sent by his mother.

She continued:”He made his name on Geordie Shore and won Celebrity Big Brother but that was as far back as 2016.

“Although he’s done some TV work since Geordie Shore ended in 2019 those were the programmes he made his name from.

“He now relies extensively on the promotional world being paid to attend bars and nightclubs for events.”

She said his opening and closing balances for the last three months “make for bleak reading”.

Timlin has recently become a father, and opened up to The Sun about how his son has changed his life.

He joined Geordie Shore in 2012 and gained himself the nickname Turbo T for his womanising ways.

Admitting he was out seven days a week doing cocaine as he opened up about his drug-drive arrest for the first time, he told us: “I felt like I was just getting drunk and I was on coke and all sorts,” he admits.

“It was just like every night getting drunk, waking up and then going out again.”

Timlin, 37, was fined £938, Oukhellou £975 and Clayton was given a £820 fine. All the celebs will pay a £1,000 contribution to prosecution costs.

Published on
04/02/2026 – 12:42 GMT+1

Novo Nordisk shares fell sharply on Wednesday after the company warned that sales and profits will drop in 2026.

The Danish drugmaker’s stock slid about 17% in early trading in Copenhagen, erasing gains made earlier in the year. The fall followed an unexpected pre-release of the company’s outlook for 2026.

Sales and operating profit are both expected to decline by between 5% and 13% this year, far below what analysts had anticipated.

The company had already cut its 2025 guidance in July, citing a difficult US market, triggering a one-day share price drop of more than 20%.

Pressure in the US

Novo Nordisk says it is reducing prices to make its GLP-1 drugs more affordable, even though the move is likely to hurt short-term performance.

The company faces growing competition in the United States from cheaper compounded versions of semaglutide — the active ingredient in Wegovy and diabetes drug Ozempic — as well as from rival Eli Lilly.

There have been some brighter signs. The new oral version of Wegovy has seen strong early demand in the US.

Novo Nordisk endured its worst year on record in 2025, with shares falling nearly 50%.

The company also underwent major leadership changes, appointing its first non-Danish chief executive and bringing former CEO Lars Rebien Sørensen back as chair.

At the same time, it struck a deal with US President Donald Trump for a programme tied to TrumpRx and direct-to-consumer discounts.

The starting price for the new Wegovy pill has been set at $149 (€126), far below the price of the injectable version a year earlier.

Patent expiries in several markets outside the United States are also expected to weigh on sales in 2026.

Meanwhile, the head of Novo’s US business, David Moore, who oversaw the launch of the pill, is leaving the company for personal reasons. He will be replaced by Jamie Miller, formerly of UnitedHealth.